Cogent Biosciences (UMRX) Stock Price, News & Analysis

Company Overview

Cogent Biosciences, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel immunotherapy products designed to harness the power of a patient's immune system to cure cancer. The firm's technologies include Antibody-Coupled T-cell Receptor, which is a chimeric protein that binds to tumor targeting antibodies. The company was founded by Charles Wilson and Dario Campana in March 2014 and is headquartered in Cambridge, MA.

Key Stats

• Today's Range: $7.68 to $8.06
• 50-Day Range: $2.35 to $13.01
• 52-Week Range: $0.29 to $3.72
• Volume: 2.67 million shs
• Average Volume: 1.22 million shs
• Market Capitalization: $332.96 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

UMRX Stock Analysis - Frequently Asked Questions

How were Cogent Biosciences' earnings last quarter?

Cogent Biosciences, Inc. (NASDAQ:UMRX) released its earnings results on Tuesday, August, 11th. The company reported ($0.24) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.21) by $0.03. The business earned $0.53 million during the quarter. Cogent Biosciences had a negative net margin of 96.84% and a negative trailing twelve-month return on equity of 87.78%.

When did Cogent Biosciences IPO?

Cogent Biosciences (UMRX) raised $75 million in an initial public offering (IPO) on Thursday, March 29th 2018. The company issued 5,800,000 shares at $12.00-$14.00 per share. Morgan Stanley and Cowen served as the underwriters for the IPO and SunTrust Robinson Humphrey and Wedbush Securities were co-managers.

What other stocks do shareholders of Cogent Biosciences own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Cogent Biosciences investors own include Advanced Micro Devices (AMD), Tesla (TSLA), NVIDIA (NVDA), JPMorgan Chase & Co. (JPM), Meta Platforms (META), Netflix (NFLX) and Alphabet (GOOG).

Company Calendar

• Last Earnings: 8/11/2020
• Today: 12/22/2024

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical Preparations
• Sub-Industry: N/A
• Current Symbol: NASDAQ:UMRX
• CUSIP: N/A
• CIK: 1622229
• Web: www.unumrx.com
• Phone: (617) 945-5576
• Fax: N/A
• Employees: 72
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): ($1.04)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-31,830,000.00
• Net Margins: -96.84%
• Pretax Margin: N/A
• Return on Equity: -87.78%
• Return on Assets: -52.14%

Debt

• Debt-to-Equity Ratio: 0.18
• Current Ratio: 2.90
• Quick Ratio: 2.90

Sales & Book Value

• Annual Sales: $22.50 million
• Price / Sales: 14.80
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $1.04 per share
• Price / Book: 7.54

Miscellaneous

• Outstanding Shares: 42,469,000
• Free Float: N/A
• Market Cap: $332.96 million
• Optionable: Not Optionable
• Beta: 3.93